Dr. Daniel A. Ermann, MD

Dr. Ermann practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Ermann's NPI, 1386160596, was assigned on August 18, 2017. Dr. Ermann holds Utah license 11731045-1205.

Dr. Ermann's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Ermann's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Ermann is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Ermann to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ermann practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Ermann's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dmand AI has Dr. Ermann's licenses on file in 2 states: Utah and Nebraska.

CMS data shows 1,287 Medicare services from Dr. Ermann across 7 procedure codes in 2024, for 104 Medicare patients. Medicare paid $49,629 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 104 Medicare patients who saw Dr. Ermann in 2024. The largest group is 65 to 74, with 64 patients. 67% of them have high blood pressure, and 63% have high cholesterol. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ermann's median patient age at 73, with 40% women.

In 2024, Dr. Ermann wrote 445 Medicare Part D claims for 52 patients. 81% of them were for generic drugs. CMS names the drug for 338 of them, across 12 drugs with 11 or more claims each, at $865,391 in total drug cost. In 2023, CMS named 65 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Ermann for performance year 2024, reported as part of a group. Dr. Ermann accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ermann as offering telehealth.

Dmand AI links 15 papers to Dr. Ermann, published from 2019 to 2025. 2023 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Academic Medical Centers and Leukemia, Lymphocytic, Chronic, B-Cell. Dr. Ermann has published most often in Clin Lymphoma Myeloma Leuk. Dr. Ermann's most frequent co-authors are Victoria A. Vardell, MD, Catherine C. Coombs, MD and Peter T. Silberstein, MD.

CMS Open Payments shows 86 general payments to Dr. Ermann from 15 drug and device companies from 2019 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. AstraZeneca Pharmaceuticals LP paid the most, $42,591.